Growth factor complexes and modulation of cell migration and growth
Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.
1. An isolated protein complex comprising: (i) insulin-like growth factor-I (IGF-I), or at least a domain of IGF-I which is capable of binding (a) a type I IGF receptor and (b) insulin-like growth factor binding protein 3 (IGFBP3);
(ii) IGFBP3; and
(iii) at least an integrin-binding domain of vitronectin (VN) and a polyanionic amino acid sequence corresponding to residues 53-64 of a mature VN protein (SEQ ID NO: 2) and which does not comprise a heparin-binding domain (HBD) of VN.
2. The isolated protein complex of claim 1 , wherein said at least a domain of IGF-I which is capable of binding a type I IGF receptor includes residue 24 of IGF-I.
3. The isolated protein complex of claim 2 wherein residue 24 is not leucine.
4. The isolated protein complex of claim 1 , wherein VN not comprising a HBD is a naturally-occurring form of VN.
5. The isolated protein complex of claim 1 , wherein VN not comprising a HBD is a truncated fragment of VN.
6. The isolated protein complex of claim 1 , wherein VN not comprising a HBD is VN or a fragment thereof wherein the HBD has been deleted or mutated.
7. The isolated protein complex of claim 1 , wherein the integrin-binding domain is an α v integrin-binding domain.
8. The isolated protein complex of claim 7 , wherein the integrin-binding; domain is an α v β 3 integrin-binding domain or an α v β 5 integrin-binding domain.
9. An isolated protein complex in the form of a synthetic chimeric protein comprising an amino acid sequence of:
(i) insulin-like growth factor-I (IGF-I) or at least a domain of IGF-which is capable of binding a type I IGF receptor; and
(ii) at least an integrin-binding domain of vitronectin (VN) which does not comprise a heparin-binding domain (HBD).
10. The isolated protein complex of claim 9 , wherein the integrin-binding domain is an α v integrin-binding domain.
11. The isolated protein complex of claim 10 , wherein the integrin-binding domain is an α v β 3 integrin-binding domain or an α v β 5 integrin-binding domain.
12. The isolated protein complex of claim 9 , wherein vitronectin (VN) or said at least an integrin-binding domain of VN does not comprise a polyanionic amino acid sequence corresponding to residues 53-64 of a mature VN protein (SEQ ID NO: 2).
13. The isolated protein complex of claim 9 , which does not comprise an IGFBP amino acid sequence.
14. The isolated protein complex of claim 9 , wherein said at least a domain of IGF-I which is capable of binding a type I IGF receptor includes residue 24 of IGF-I.
15. The isolated protein complex of claim 9 , comprising amino acid residues 1 to 52 of vitronectin (SEQ ID NO: 2).
16. The isolated protein complex of claim 9 , comprising amino acid residues 1 to 130 of vitronectin (SEQ ID NO: 2).
17. The isolated protein complex of claim 9 , comprising amino acid residues 4 to 70 of IGF-I (SEQ ID NO: 3).
18. The isolated protein complex of claim 9 , comprising amino acid residues 1 to 70 of IGF-I (SEQ ID NO: 3).
19. The isolated protein complex of claim 9 , further comprising at least one linker sequence.
20. The isolated protein complex of claim 19 , wherein the linker sequence comprises a protease cleavage site.
21. The isolated protein complex of claim 19 , wherein the linker sequence is selected from the group consisting of:
(i)
Gly 4 Ser
(SEQ ID NO:4);
(ii)
Gly 4 Ser 3
(SEQ ID NO:5);
(iii)
(Gly 4 Ser) 3
(SEQ ID NO:6);
(iv)
Leu Ile Lys Met Lys Pro
(SEQ ID NO:7);
and
(v)
Gln Pro Gln Gly Leu Ala Lys
(SEQ ID NO:8).
22. The isolated protein complex of claim 1 , which comprises one amino acid mutation in VN.
23. The isolated protein complex of claim 22 , wherein the mutation is selected from the group consisting of: (i) T50A; (ii) T57A; (iii) T50E; and (iv) T57E.
24. The isolated protein complex of claim 9 comprising the amino acid sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 12.
25. A pharmaceutical composition comprising the isolated protein complex of claim 1 and a pharmaceutically-acceptable carrier, diluent or excipient.
26. A surgical implant, scaffold or prosthesis impregnated, coated or otherwise comprising the isolated protein complex of claim 1 .
27. A wound or burn dressing comprising the isolated protein complex of claim 1 .
28. A pharmaceutical composition comprising the isolated protein complex of claim 9 , and a pharmaceutically-acceptable carrier, diluent or excipient.
29. A surgical implant, scaffold or prosthesis impregnated, coated or otherwise comprising the isolated protein complex of claim 9 .
30. A wound or burn dressing comprising the isolated protein complex of claim 9 .
31. The isolated protein complex of claim 1 , which is a non-covalently associated complex.
32. The isolated protein complex of claim 9 , which further comprises a polyanionic amino acid sequence corresponding to residues 53-64 of a mature VN protein (SEQ ID NO: 2).